Form 4: Alphatec EVP Awarded Performance-Based RSUs

Alphatec Holdings' EVP of People & Culture, Craig E. Hunsaker, received significant restricted stock unit awards, including performance-based grants tied to stock price and operational targets.

Summary

• Craig E. Hunsaker, EVP, People & Culture, was awarded a total of 459,480 common stock RSUs and up to 127,378 performance-based derivative RSUs on February 25, 2026.
• 311,110 RSUs were awarded based on the satisfaction of performance criteria for the fiscal year ended December 31, 2025, vesting in three equal installments on March 5, 2026, March 5, 2027, and March 5, 2028.
• An additional 127,378 RSUs were granted, vesting in three equal installments on March 5, 2027, March 5, 2028, and March 5, 2029.
• 20,992 RSUs were granted in lieu of a portion of the 2025 cash bonus, vesting on December 4, 2026.
• Two separate performance-based RSU awards, each for up to 63,689 units, were granted with vesting tied to achieving common stock 30-day average trading prices of $25.00 (by Dec 31, 2028) and $36.00 (by Dec 31, 2030), and specific operational metrics.
• Following these transactions, Hunsaker beneficially owns 1,842,576 shares of common stock and 127,378 derivative restricted stock units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating strong executive alignment with long-term shareholder value through performance-based compensation and reflecting confidence in future growth targets.

Positives

• Significant RSU awards to a key executive, aligning management interests with shareholder value.
• Inclusion of performance-based RSUs tied to specific stock price targets ($25.00 and $36.00) and operational metrics, indicating a focus on long-term growth and performance.
• The compensation committee's confirmation of performance criteria satisfaction for a prior award (311,110 RSUs) suggests the company met its internal goals for FY2025.

Negatives

• The issuance of new RSUs could lead to future share dilution upon vesting, though this is a standard component of executive compensation.

Future Outlook

The company's future outlook, as implied by these awards, includes a focus on achieving specific stock price targets of $25.00 by December 31, 2028, and $36.00 by December 31, 2030, alongside the attainment of defined operational metrics. These targets suggest management's confidence in long-term growth and value creation.

Management Comments

• The issuer's compensation committee confirmed the satisfaction of certain performance criteria for the fiscal year ended December 31, 2025.
• The issuer elected to grant RSUs to the reporting person in lieu of a portion of the reporting person's 2025 cash bonus.
• The grant amount was determined using the 30-day average trading price of the issuer's common stock as of close of market on February 25, 2026.

Industry Context

StockSavvy.ai notes that the use of performance-based restricted stock units, tied to both stock price appreciation and operational achievements, is a common and effective executive compensation strategy in the medical technology and orthopedic device industry. This approach aims to align executive incentives directly with long-term shareholder value creation and strategic business objectives, a practice widely adopted by peers to attract and retain top talent.

Comparison to Industry Standards

• The structure of these RSU awards, particularly the inclusion of stock price targets and operational metrics, aligns with best practices observed in the broader medical device and biotechnology sectors.
• For instance, companies like Stryker (SYK) and Zimmer Biomet (ZBH) frequently utilize similar long-term incentive plans to motivate executives towards achieving specific financial and strategic milestones.
• The $25.00 and $36.00 stock price targets, while specific to Alphatec, reflect ambitious growth expectations comparable to those set by high-growth companies in the sector aiming for significant market penetration or product innovation success.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution from RSU vesting, but also increased alignment of executive incentives with long-term stock performance and operational success.
• Employees (Executive): Enhanced long-term compensation and motivation tied to company performance.

Next Steps

• Vesting of 311,110 RSUs on March 5, 2026, March 5, 2027, and March 5, 2028.
• Vesting of 127,378 RSUs on March 5, 2027, March 5, 2028, and March 5, 2029.
• Vesting of 20,992 RSUs on December 4, 2026.
• Achievement of common stock 30-day average trading price of $25.00 by December 31, 2028, for performance-based RSUs.
• Achievement of common stock 30-day average trading price of $36.00 by December 31, 2030, for performance-based RSUs.
• Achievement of certain operational metrics by December 31, 2028, and December 31, 2030, for performance-based RSUs.

Key Dates

Recommendation

The filing details standard executive compensation through RSU grants, including performance-based awards. While these awards align executive interests with shareholder value and indicate management's confidence in future growth targets, they do not present new fundamental information that would warrant a change in investment thesis. The potential for future dilution is a consideration, but it is a common aspect of executive compensation. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while monitoring the company's progress towards the stated performance targets.

Keywords

Alphatec Holdings, ATEC, SEC Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Trading, Performance-Based Awards, Stock Awards, Corporate Governance